Wanbing Liu

Prof. Wanbing Liu


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 March 2020 in medRxiv
Verified
Preprint
Open access
PDF file
PZPingping Zhang
Pingping Zhang
QGQi Gao
Qi Gao
TWTang Wang
Tang Wang
YKYuehua Ke
Yuehua Ke
FMFei Mo
Fei Mo
YZYong Zhao
Yong Zhao
Background: The colloidal gold immunochromatography assay (GICA) is a rapid diagnostic tool for novel coronavirus disease 2019 (COVID-19) infections. However, with significant numbers of false negatives, improvements to GICA are needed. Methods: Six recombinant HCoV-19 nucleocapsid and spike proteins were prepared and evaluated. The optimal proteins were employed to develop a sandwich-format GICA strip to detect total antibodies (IgM and IgG) against HCoV-19. GICA’s performance was assessed with comparison of viral RNA detection. Results: Recombinant HCoV-19 proteins were obtained, including three prokaryotically expressed rN, rN1, rN2 nucleocapsid proteins, and three eukaryotically expressed rS1, rS-RBD, rS-RBD-mFc spike proteins. The recombinant proteins with the highest ELISA titers (rS1 and rS-RBD-mFc) against coronavirus-specific IgM and IgG were chosen for GICA development. The GICA has a sensitivity and specificity of 86.89% (106/122) and 99.39% (656/660), respectively. Furthermore, 65.63% (21/32) of the clinically confirmed but RT-PCR negative samples were GICA positive. Conclusions: The eukaryotically-expressed spike proteins (rS1and rS-RBD-mFc) are more suitable than the prokaryotically expressed nucleocapsid proteins for HCoV-19 serological diagnosis. The GICA sandwich used to detect total antibodies is a powerful complement to the current standard RNA-based tests.

20 March 2020 in medRxiv
Verified
Preprint
Open access
PDF file
WLWanbing Liu
Wanbing Liu
LLLei Liu
Lei Liu
GKGuomei Kou
Guomei Kou
YZYaqiong Zheng
Yaqiong Zheng
YDYinjuan Ding
Yinjuan Ding
GZgen shan Zheng
gen shan Zheng
Background: At present, PCR-based nucleic acid detection cannot meet the demands for coronavirus infectious disease (COVID-19) diagnosis. Methods: 214 confirmed COVID-19 patients who were hospitalized in the General Hospital of Central Theater Command of the People’s Liberation Army between January 18 and February 26, 2020, were recruited. Two Enzyme-Linked Immunosorbent Assay (ELISA) kits based on recombinant SARS-CoV-2 nucleocapsid protein (rN) and spike protein (rS) were used for detecting IgM and IgG antibodies, and their diagnostic feasibility was evaluated. Results: Among the 214 patients, 146 (68.2%) and 150 (70.1%) were successfully diagnosed with the rN-based IgM and IgG ELISAs, respectively; 165 (77.1%) and 159 (74.3%) were successfully diagnosed with the rS-based IgM and IgG ELISAs, respectively. The positive rates of the rN-based and rS-based ELISAs for antibody (IgM and/or IgG) detection were 80.4% and 82.2%, respectively. The sensitivity of the rS-based ELISA for IgM detection was significantly higher than that of the rN-based ELISA. We observed an increase in the positive rate for IgM and IgG with an increasing number of days post-disease onset (d.p.o.), but the positive rate of IgM dropped after 35 d.p.o. The positive rate of rN-based and rS-based IgM and IgG ELISAs was less than 60% during the early stage of the illness 0-10 d.p.o., and that of IgM and IgG was obviously increased after 10 d.p.o. Conclusions: ELISA has a high sensitivity, especially for the detection of serum samples from patients after 10 d.p.o, it can be an important supplementary method for COVID-19 diagnosis.

8 March 2020 in medRxiv
Verified
Preprint
Open access
PDF file
LLLei Liu
Lei Liu
WLWanbing Liu
Wanbing Liu
SWShengdian Wang
Shengdian Wang
GZgen shan Zheng
gen shan Zheng
Background: The outbreak of the recently emerged novel corona virus disease 2019 (COVID-19) poses a challenge for public health laboratories. We aimed to evaluate the diagnostic value of serological assay for SARS-CoV-2. Methods: A newly-developed ELISA assay for IgM and IgG antibodies against N protein of SARS-CoV-2 were used to screen the serums of 238 admitted hospital patients with confirmed or suspected SARS-CoV-2 infection from February 6 to February 14, 2020. SARS-CoV-2 RNA was detected by real time RT-PCR on pharyngeal swab specimens. Findings: Of the 238 patients, 194 (81.5%) were detected to be antibody (IgM and/or IgG) positive, which was significantly higher than the positive rate of viral RNA (64.3%). There was no difference in the positive rate of antibody between the confirmed patients (83.0%, 127/153) and the suspected patients (78.8%, 67/85) whose nucleic acid tests were negative. After the patients were defined to the different stages of disease based on the day when the test samples were collected, the analysis results showed that the antibody positive rates were very low in the first five days after initial onset of symptoms, and then rapidly increased as the disease progressed. After 10 days, the antibody positive rates jumped to above 80% from less than 50%. On the contrary, the positive rates of viral RNA kept above 60% in the first 11 days after initial onset of symptoms, and then rapidly decreased. In addition, half of the suspected patients with symptoms for 6-10 days were detected to be antibody positive. Interpretation: The suspected patients were most likely infected by SARS-CoV-2. Before the 11th day after initial onset of symptoms, nucleic acid test is important for confirmation of viral infection. The combination of serological assay can greatly improve the diagnostic efficacy. After that, the diagnosis for viral infection should be majorly dependent on serological assay.

10 May 2023 in Vaccines
Verified
Journal Article
Open access
PDF file
YHYingyu He
Yingyu He
FZFang Zhang
Fang Zhang
YLYan Liu
Yan Liu
ZXZhou Xiong
Zhou Xiong
GZgen shan Zheng
gen shan Zheng
LLLei Liu
Lei Liu
For SARS-CoV-2 mutants, the effectiveness of the COVID-19 vaccines is still controversial. In this study, we aimed to investigate the clinical characteristics of Omicron-infected patients who completed primary immunization and booster immunization, respectively, during the rapid propagation of the Omicron variant in China. A total of 932 patients with confirmed SARS-CoV-2 infection from 18 December 2022 to 1 January 2023 were included in this survey by filling out questionnaires online. The enrolled patients were divided into the primary immunization group and the booster immunization group according to their vaccination status. During the whole course of disease, the most frequent symptoms were fever (90.6%), cough (84.3%), weakness (77.4%), headache and dizziness (76.1%), and myalgia (73.9%). Nearly 90% of the patients had symptoms lasting for less than 10 days, and 39.8% of the patients ended the course of the disease in 4–6 days. A total of 58.8% of these patients had a fever with a maximum body temperature of over 38.5 °C. Moreover, 61.4% of the patients had a fever that lasted less than 2 days. There were no obvious differences in initial symptoms, cardinal symptoms, symptom duration time, maximum body temperature, and fever duration time between the two groups of patients. In addition, no significant difference was found in the positive or negative conversion time of SARS-CoV-2 antigen/nucleic acid between the two groups of patients. For mild patients with Omicron breakthrough infection, enhanced immunization has no significant impact on the clinical performance and duration of viral infection compared with primary immunization. The reasons behind the different clinical manifestations of patients with mild symptoms after the breakthrough infection of the Omicron strain are still worth further research. Heterologous vaccination may be a better strategy for enhanced immunization, which can help improve the immune protection ability of the population. Further research should be carried out on vaccines against mutant strains and spectral anti-COVID-19 vaccines.

2 February 2026 in Frontiers in Cellular and Infection Microbiology
Verified
Journal Article
Open access
PDF file
YLYan Liu
Yan Liu
LLLei Liu
Lei Liu
JDJinbing Du
Jinbing Du
WNWenxu Ni
Wenxu Ni
TZTingting Zou
Tingting Zou
WLWanbing Liu
Wanbing Liu
Platelet-rich plasma (PRP) is known as an autologous biological agent that can immensely promote wound healing. Bacterial infection is a common complication of wounds which obstructs wound healing. However, the effect of PRP on bacteria is still inconclusive. This in vitro study evaluated the antibacterial activity of PRP, platelet-poor plasma (PPP) and Frozen-PRP (Fro-PRP) against Escherichia coli , Klebsiella pneumoniae , Enterobacter cloacae , Staphylococcus aureus , and Enterococcus faecalis . The antimicrobial activity was performed using modified agar diffusion method, colony-forming units counting test, and bacterial growth curve analysis. The results showed that PRP, PPP and Fro-PRP had antimicrobial effects on five bacterial strains including Escherichia coli , Klebsiella pneumoniae , Enterobacter cloacae , Staphylococcus aureus , and Enterococcus faecalis . The antimicrobial activity of PRP was significantly stronger than that of Fro-PRP and PPP. To a certain extent, frozen storage may reduce the antibacterial ability of PRP. Overall, our study demonstrates that PRP and other platelet derived products seem to be a promising alternative tool for infected wounds treatment.

27 March 2026 in Frontiers in Cell and Developmental Biology
Verified
Journal Article
Open access
PDF file
YHYingyu He
Yingyu He
XWXiaojie Wei
Xiaojie Wei
YXYingkai Xu
Yingkai Xu
ZYZihan Yuan
Zihan Yuan
JLJunying Li
Junying Li
LLLei Liu
Lei Liu
Background: Whole blood (WB) resuscitation is a critical component of trauma care. Leukoreduction (LR) is commonly employed to mitigate transfusion-related risks. We aimed to understand the effects of LR on the functionality and metabolism of various components in refrigerated WB and provide new strategies for WB application in trauma treatment. Methods: Ten bags of WB (400 mL ± 10%) were split into paired samples with and without LR and stored at 4°C ± 2 °C for 35 days. Storage-lesion tests were performed every 7 days from the day of blood collection. Descriptive heatmaps and weighted gene co-expression network analysis (WGCNA) were used to characterize global patterns of indicator change, while exploratory mediation models and penalized regression (LASSO) were applied to investigate pathways and rank variables associated with clot strength. Results: Descriptive heatmaps and exploratory WGCNA analyses suggested two distinct temporal patterns: platelet-related and viscoelastic indicators decreased progressively, whereas metabolic, hemolytic, and electrolyte indicators increased over time. On Day 0 (immediately after leukoreduction), leukoreduced whole blood (LR-WB) had a markedly lower platelet count than paired nonleukoreduced whole blood group (NLR-WB) (23.40 ± 2.00 vs. 185.20 ± 2.93 *10 9 /L; p < 0.05), accompanied by reduced clot strength and impaired kinetics (MA 33.6 ± 9.82 vs. 61.09 ± 2.97 mm; K 5.20 ± 1.37 vs. 1.70 ± 0.35 min; Angle 45.83 ± 8.82 vs. 65.68° ± 4.33°; all p < 0.05). These between-group differences persisted across storage. Fibrinogen concentration remained comparable between two groups, but kinetic indicators (K, Angle) were consistently lower in LR-WB. In exploratory mediation models, platelet count, mean platelet volume, K, and Angle accounted for most of the model-based associations of LR and storage duration with MA. Penalized regression (LASSO) further highlighted blood cells’ (RBCs’) phosphatidylserine (PS) exposure and hemoglobin (FHb) as late-storage features associated with lower MA within this experimental dataset. Conclusion: LR was associated with early platelet-driven hemostatic impairment, and storage time appeared to progressively shift injury mechanisms toward RBC membrane instability, hemolysis, and metabolic stress. RBCs’ PS exposure and FHb can serve as candidate indicators associated with clot strength.